来那度胺为基础方案治疗57例复发或难治性多发性骨髓瘤患者的结局
本研究回顾性分析2013年6月至2016年2月收治的57例复发或难治性多发性骨髓瘤患者,均接受来那度胺为基础的化疗。总体缓解率为58.9%(33/56),中位无进展生存期8个月,中位总体生存期19个月。染色体核型异常和R-ISS分期Ⅲ期是独立预后不良因素。
要点
- 来那度胺为基础方案治疗复发或难治性MM的ORR为58.9%(33/56),临床获益率69.6%。
- 中位随访27个月,中位PFS 8个月,中位OS 19个月。
- 染色体核型异常和R-ISS分期Ⅲ期是独立预后不良因素。
核心结论
- 来那度胺为基础的化疗方案在复发或难治性MM患者中有效率高、耐受性良好。
- 染色体核型异常和R-ISS分期Ⅲ期是该患者群体中的独立预后不良因素。
研究设计与样本
- 回顾性分析2013年6月至2016年2月收治的57例复发或难治性多发性骨髓瘤患者,均接受来那度胺为基础的化疗。
主要发现
- ISS Ⅲ期患者占60.4%,R-ISS Ⅲ期占37.9%,53.3%的患者存在高危遗传学异常。
- 来那度胺中位疗程为6(1~32)个,ORR为58.9%(33/56),其中CR 8.9%、VGPR 19.8%、PR 30.4%,MR 10.7%,临床获益率69.6%。
- 前期接受一线以上治疗、既往沙利度胺耐药及R-ISS Ⅲ期患者ORR较低。
- 中位随访27个月,中位PFS 8个月,中位达PR时间2个月,中位DOR 8个月,中位OS 19个月。
- 单因素分析显示染色体核型异常、R-ISS Ⅲ期、疗效未达PR及以上是影响PFS和OS的不良因素;多因素分析显示染色体核型异常和R-ISS Ⅲ期为独立预后因素。
关键数值与推荐
- 最常见3/4级非血液学不良反应为感染(17.5%)、皮疹(1.8%)、血栓(1.8%)。
- 最常见3/4级血液学不良反应为中性粒细胞减少(7.0%)和血小板减少(3.5%)。
- 3例(5.3%)患者因不良反应停药,观察到第二肿瘤2例(3.5%)。
临床怎么用
- 来那度胺为基础的化疗方案可用于复发或难治性MM患者的治疗。
- 染色体核型异常和R-ISS分期Ⅲ期患者预后较差,需关注其治疗策略。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To investigate the clinical efficacy and safety of lenalidomide (Revlimid, R) -based chemotherapy in the treatment of relapsed/refractory multiple myeloma (MM) patients. Methods: 57 consecutively relapsed/refractory MM patients were retrospectively analyzed from June 2013 to February 2016. All the patients received lenalidomide-based chemotherapy. Results: ① 60.4% patients had international staging system (ISS) stage Ⅲ, 37.9% patients had revised international staging system (R-ISS) stage Ⅲ, and 53.3% patients harbored at least one of the high-risk cytogenetic abnormalities[del (17p) and/or t (4;14) and/or t (14;16) ]. ②The patients received median 6 cycles of R (range: 1-32). The overall response rate (ORR) was 58.9% (33/56) , among which 8.9% was complete response (CR) , 19.8% was very good partial response (VGPR) , and 30.4% was partial response (PR). In addition, 10.7% patients attained minor response (MR). Total clinical benefit was 69.6%. Patients with more than 1 line of prior therapy, or previously thalidomide-resistance, or R-ISS stage Ⅲ disease showed significantly lower ORR. ③With a median follow-up of 27 months, the median progression free survival (PFS) , the median interval to PR, the median duration of response (DOR) , and the median overall survival (OS) was 8 months, 2 months, 8 months, and 19 months, respectively. Univariate prognostic analysis showed that abnormal karyotype, R-ISS stage Ⅲ and response inferior to PR were negative prognostic factors for PFS and OS. While the multivariate prognostic analysis showed that abnormal karyotype and R-ISS stage Ⅲ were independent prognostic factors. ④In the safety aspect, the most common grade 3-4 non-hematology adverse events (AEs) were infection (17.5%) , rash (1.8%) and thromboembolism (1.8%) , and the most common grade 3-4 hematology AEs were neutropenia (7.0%) and thrombocytopenia (3.5%). Totally 3 patients (5.3%) discontinued R because of AEs, and 2 cases (3.5%) of secondary primary malignancies were observed. Conclusion: The R-based treatment is effective and safe in the treatment of relapsed/refractory MM patients in China. Abnormal karyotype and R-ISS stage Ⅲ were independent negative prognosis factors in this cohort. 目的: 探讨来那度胺(商品名瑞复美)为基础的化疗方案在复发或难治性多发性骨髓瘤(MM)患者中的疗效及安全性。 方法: 回顾性分析2013年6月至2016年2月收治的57例应用来那度胺为基础的方案治疗的复发或难治性MM患者资料。 结果: ①国际分期系统(ISS)Ⅲ期患者比例为60.4%,修改的国际分期系统(R-ISS)Ⅲ期患者比例为37.9%,53.3%的患者存在高危遗传学异常。②患者应用来那度胺中位疗程为6(1~32)个。治疗的总体缓解率(ORR)为58.9%(33/56),其中完全缓解率为8.9%,非常好的部分缓解率为19.8%,部分缓解(PR)率为30.4%。此外有10.7%(6/56)的患者达到微小缓解,临床获益率69.6%。前期接受一线以上治疗、既往沙利度胺耐药及R-ISS Ⅲ期患者ORR较低。③中位随访27个月,患者中位无进展生存(PFS)时间8个月,中位达PR时间2个月,中位缓解持续时间(DOR)8个月,中位总体生存(OS)时间19个月。单因素分析中,染色体核型异常、R-ISS分期Ⅲ期、疗效未达PR及以上是影响患者PFS和OS的不良因素。多因素分析显示,染色体核型异常、R-ISS分期Ⅲ期具有独立预后意义。④安全性分析显示,最常见的3/4级非血液学不良反应为感染(17.5%)、皮疹(1.8%)、血栓(1.8%)。最常见的3/4级血液学不良反应为中性粒细胞减少(7.0%)和血小板减少(3.5%)。共有3例(5.3%)患者因不良反应停药。共观察到第二肿瘤2例(3.5%)。 结论: 来那度胺为基础的化疗方案在复发或难治性MM患者中有效率高、耐受性良好。预后因素分析显示,在这一患者群体中染色体核型异常、R-ISS分期Ⅲ期是独立预后不良因素。.
引用
- Deng SH, Xu Y, Sui WW, et al. [Outcomes of lenalidomide-based treatment for 57 patients of relapsed or refractory multiple myeloma]. Zhonghua Xue Ye Xue Za Zhi. 2017. PMID: 28655091. doi:10.3760/cma.j.issn.0253-2727.2017.06.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。